Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...

Intuitive Surgical (ISRG), and Insulet (PODD) stocks were cited as top MedTech stock picks for 2025 by J.P. Morgan. Read more ...

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also ...

The revised price target comes as Thibault anticipates a boost in U.S. sales of the Omnipod insulin management system, particularly in the second half of 2025, due to expanded marketing efforts ...

The revised price target comes as Thibault anticipates a boost in U.S. sales of the Omnipod insulin management system, particularly in the second half of 2025, due to expanded marketing efforts aimed ...

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD – Research Report), with a price target of ...

Insulet (NASDAQ: PODD) recently received a number of ratings updates from brokerages and research firms: 12/12/2024 – Insulet had its price target raised by analysts at JPMorgan Chase & Co. from $280.

In December, a Massachusetts corporation won the largest jury verdict ever awarded under the federal Defend Trade Secrets Act ...

Surreal” is how Kelsey Bascom describes her journey with Type 1 diabetes. That about covers how the actor and filmmaker went ...